Antidepressive Agents, Second-Generation
"Antidepressive Agents, Second-Generation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
| Descriptor ID |
D018687
|
| MeSH Number(s) |
D27.505.954.427.700.122.050
|
| Concept/Terms |
Antidepressive Agents, Second-Generation- Antidepressive Agents, Second-Generation
- Antidepressive Agents, Second Generation
- Second-Generation Antidepressive Agents
- Agents, Second-Generation Antidepressive
- Second Generation Antidepressive Agents
- Atypical Antidepressants
- Antidepressants, Atypical
- Antidepressive Drugs, Second-Generation
- Antidepressive Drugs, Second Generation
- Drugs, Second-Generation Antidepressive
- Second-Generation Antidepressive Drugs
|
Below are MeSH descriptors whose meaning is more general than "Antidepressive Agents, Second-Generation".
Below are MeSH descriptors whose meaning is more specific than "Antidepressive Agents, Second-Generation".
This graph shows the total number of publications written about "Antidepressive Agents, Second-Generation" by people in this website by year, and whether "Antidepressive Agents, Second-Generation" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 2 | 0 | 2 |
| 2005 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 2 | 0 | 2 |
| 2017 | 9 | 3 | 12 |
| 2018 | 6 | 1 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Antidepressive Agents, Second-Generation" by people in Profiles.
-
Discontinuation Syndrome of Extended-Release Venlafaxine during the COVID-19 Epidemic. Psychiatr Danub. 2021; 33(1):121-122.
-
Is bupropion useful in the treatment of post-stroke thalamic apathy? A case report and considerations. Funct Neurol. 2018 Oct/Dec; 33(4):213-216.
-
Bilateral sciatic neuropathy with severe rhabdomyolysis following venlafaxine overdose: A case report. Medicine (Baltimore). 2018 Sep; 97(37):e12220.
-
Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. JAMA. 2018 07 24; 320(4):350-358.
-
Executive Function Predicts Antidepressant Treatment Noncompletion in Late-Life Depression. J Clin Psychiatry. 2018 May/Jun; 79(3).
-
Antidepressant Prescription and Risk of Lung Cancer: A Nationwide Case-Control Study. Pharmacopsychiatry. 2019 Mar; 52(3):134-141.
-
Treatment expectancy and working alliance in pharmacotherapy as predictors of outcomes in complicated grief. J Consult Clin Psychol. 2018 04; 86(4):367-371.
-
Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment. J Psychiatr Res. 2018 07; 102:1-7.
-
Effect of Metabolic Syndrome on Late-Life Depression: Associations with Disease Severity and Treatment Resistance. J Am Geriatr Soc. 2017 Dec; 65(12):2651-2658.
-
Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study). BMC Pharmacol Toxicol. 2017 11 07; 18(1):70.